Elevated Hemoglobin A 2 : A Molecular Revisited, and Implications to β‐Thalassemia Screening
Journal of Clinical Laboratory Analysis · 2026-08 · 40 (15)
DOI: 10.1002/jcla.70294 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 25.06.2026. Verfasst von Kritsada Singha und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thai…. Hauptthemen laut MEDLINE: beta-Thalassemia, Hemoglobin A2. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Khon Kaen University, Health Systems Research Institute.
Abstract (Originalsprache)
Background
In Thailand, the Hb A 2 cut‐off value for β‐thalassemia carrier has been changed from 4.0% to 3.6% since 2015. We examined the molecular basis of β‐thalassemia in a large cohort of Thai subjects with this change.
Methods
A total of 36,313 retrospective specimens encountered during January 2016 to June 2025 were reviewed, and 5909 subjects (16.7%) with Hb A 2 ≥ 3.6% were recruited. Diagnosis of thalassemia was based on Hb and DNA analyses.
Results
Among the 5909 subjects, 5395 (91.3%) had Hb A 2 A, 115 (1.9%) carried Hb variants, and the remaining 399 (6.8%) resulted from misinterpretations. Of 5395 subjects, 5117 (94.8%) carried β‐thalassemia, 189 (3.5%) had normal β‐globin genes, and 89 (1.6%) had incomplete molecular analysis. Fifty different β‐thalassemia genes were identified, including nine hitherto undescribed in Thailand and two novel mutations, β CD81(CTC > CTA) and β IVSII‐713(G > A) . Falsely elevated Hb A 2 was found in 364 of 399 (70.8%) subjects with misinterpretation, 20 (3.9%) represented human errors, and 15 (2.9%) resulted from Hb E blood transfusion. A low proportion of β 0 ‐ and a high proportion of β + ‐thalassemias, a normal β‐globin gene, and diagnostic errors were observed at borderline Hb A 2 levels.
Conclusions
A change in the Hb A 2 cut‐off can alter the molecular spectrum of β‐thalassemia in Thailand. The molecular basis of β‐thalassemia was updated to include 50 mutations, both new and known. Misinterpretation at borderline Hb A 2 should be aware and cost‐effectiveness should be considered at the screening of β‐thalassemia in the region.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.
- Biomedical Science Research Unit, Faculty of Medicine, Mahasarakham University, Mueang Maha Sarakham, Mahasarakham, Thailand.
ORCID-Profile: Kritsada Singha, Supan Fucharoen
Förderung
- Khon Kaen University
- Health Systems Research Institute
Zitieren
APA
Singha, K., Pansuwan, A., Srivorakun, H., Chaibunruang, A., Yamsri, S., Tepakhan, W., Sanchaisuriya, K., Fucharoen, G., & Fucharoen, S. (2026). Elevated Hemoglobin A 2 : A Molecular Revisited, and Implications to β‐Thalassemia Screening. Journal of Clinical Laboratory Analysis, 40(15). https://doi.org/10.1002/jcla.70294
Vancouver
Singha K, Pansuwan A, Srivorakun H, Chaibunruang A, Yamsri S, Tepakhan W, et al. Elevated Hemoglobin A 2 : A Molecular Revisited, and Implications to β‐Thalassemia Screening. Journal of Clinical Laboratory Analysis. 2026;40(15). doi:10.1002/jcla.70294
BibTeX
@article{Singha2026,
author = {Singha, Kritsada and Pansuwan, Anupong and Srivorakun, Hataichanok and Chaibunruang, Attawut and Yamsri, Supawadee and Tepakhan, Wanicha and Sanchaisuriya, Kanokwan and Fucharoen, Goonnapa and Fucharoen, Supan},
title = {Elevated Hemoglobin A 2 : A Molecular Revisited, and Implications to β‐Thalassemia Screening},
journal = {Journal of Clinical Laboratory Analysis},
year = {2026},
volume = {40},
number = {15},
doi = {10.1002/jcla.70294}
}
EUVIMED